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Abstract
Background: The Hippo pathway regulates organ size by inhibiting cell proliferation and promoting cell apoptosis upon its
activation. The Yes Associated Protein 1 (YAP1) is a nuclear effector of the Hippo pathway that promotes cell growth as a
transcription co-activator. In human cancer, the YAP1 gene was reported as amplified and over-expressed in several tumor
types.
Methods: Immunohistochemical staining of YAP1 protein was used to assess the expression of YAP1 in pancreatic tumor
tissues. siRNA oligonucleotides were used to knockdown the expression of YAP1 and their effects on pancreatic cancer cells
were investigated using cell proliferation, apoptosis, and anchorage-independent growth assays. The Wilcoxon signed-rank,
Pearson correlation coefficient, Kendall’s Tau, Spearman’s Rho, and an independent two-sample t (two-tailed) test were used
to determine the statistical significance of the data.
Results: Immunohistochemistry studies in pancreatic tumor tissues revealed YAP1 staining intensities were moderate to
strong in the nucleus and cytoplasm of the tumor cells, whereas the adjacent normal epithelial showed negative to weak
staining. In cultured cells, YAP1 expression and localization was modulated by cell density. YAP1 total protein expression
increased in the nuclear fractions in BxPC-3 and PANC-1, while it declined in HPDE6 as cell density increased. Additionally,
treatment of pancreatic cancer cell lines, BxPC-3 and PANC-1, with YAP1-targeting siRNA oligonucleotides significantly
reduced their proliferation in vitro. Furthermore, treatment with YAP1 siRNA oligonucleotides diminished the anchorage-
independent growth on soft agar of pancreatic cancer cells, suggesting a role of YAP1 in pancreatic cancer tumorigenesis.
Conclusions: YAP1 is overexpressed in pancreatic cancer tissues and potentially plays an important role in the clonogenicity
and growth of pancreatic cancer cells.
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Introduction
As one of the most lethal forms of human disease, pancreatic
cancer has a one-year and five-year survival rate of 26% and 6%,
respectively [1]. There exists a critical need for novel treatment
strategies to provide a purposeful effect on the survival of patients
with pancreatic cancer.
The Hippo pathway regulates organ size by inhibiting cell
proliferation and promotes cell apoptosis [2,3]. Components of
Hippo pathway were identified in genetic mosaic screens in
Drosophila, which consist of the Hippo (Hpo) kinase, the Salvador
(Sav) adaptor protein, the Wts protein kinase, the Mats adaptor
protein, and the Yorkie (Yki) nuclear transcriptional co-activator.
Upon pathway activation, Hpo and Sav phosphorylates and
activates Wts in conjunction with Mats. Wts phosphorylates Yki to
inactivate and retain it in the cytoplasm. In mammals, the
components of the Hippo pathway are highly conserved homologs,
which include MST1/2 (Hpo), WW45 (Sav), LATS1/2 (Wts),
MOB1 (Mats), and YAP1 (Yki) [4–8].
Similar to the Drosophila model, the mammalian Hippo core
components form protein kinase complexes acting in a cascade to
phosphorylate YAP1 (also known as YAP or YAP65) and relocate
it to the cytoplasm [6,7,9,10]. As the major downstream target of
the Hippo pathway, YAP1 is a paradox. As an oncogene, the
amplification of the YAP1 gene locus at 11q22 is found in several
cancer types, including hepatocellular carcinoma, breast cancer,
oral squamous cell carcinomas, medulloblastomas, and esophageal
squamous cell carcinomas [11–15]. In addition, overexpression
of YAP1 protein and its nuclear localization have been noted
in colon, liver, lung, ovarian, and prostate cancers [6,12,16].
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YAP1 in an immortalized epithelial cell line MCF10A resulted in
its oncogenic transformation [11]. In contrast, YAP1 was also
found to stabilize and enhance p73-dependent apoptotic cell death
during cisplatin-induced DNA damage [17]. AKT, a key player in
multiple cellular survival pathways, has been shown to phosphor-
ylate YAP1 in order to suppress pro-apoptotic gene expression
[18]. In a subset of breast cancers, the YAP1 protein expression
was significantly decreased due to loss of heterozygosity, and
shRNA knockdown of YAP1 increased migration, invasiveness,
and enhanced tumor growth [19]. Overall, these findings suggest
that YAP1’s expression and role in cancer might be cell type and/
or cellular context dependent.
In this study, we sought to elucidate the role of YAP1 in
pancreatic cancer. We examined the YAP1 protein expression and
localization in pancreatic tumor tissues taken from patients with
pancreatic cancer and investigated the phenotypic effects of YAP1
down-regulation in cultured pancreatic cell lines. We have
determined that YAP1 is overexpressed in pancreatic tumor
tissues, and the down-regulation of YAP1 abated proliferation and
clonogenicity of cultured pancreatic cancer cells.
Materials and Methods
Cell Culture
The pancreatic cancer cell lines AsPC-1, BxPC-3, Capan-1,
CFPAC-1, HPAF-II, Hs 766T, MIA PaCa-2, and PANC-1 were
obtained from the American Type Culture Collection (ATCC)
(Manassas, VA). The cell lines were maintained in RPMI 1640
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS) (Gemini Bio-Products, Woodland, CA), penicillin
(100 U/ml), and streptomycin (100 mg/ml) (Invitrogen). The
immortalized human pancreatic ductal epithelial cell line,
HPDE6, was provided by Dr. M. S. Tsao (University of Toronto,
Canada) and cultured in keratinocyte-serum free media supple-
mented with bovine pituitary extract (30 mg/ml) and epidermal
growth factor (0.2 ng/ml) (Invitrogen) [20,21]. The immortalized
human pancreatic ductal epithelial cell line, hTERT-HPNE, was
obtained from ATCC and cultured in DMEM media supple-
mented with 20% FBS [22]. All cells were routinely cultivated in a
humidified incubator at 37uC and 5% CO2. Cell line identities
were verified as previously described [23].
Tissue Microarray and Immunohistochemistry (IHC)
A tissue microarray (TMA) was constructed from paraffin-
embedded blocks of 66 unique cases of pancreatic ductal
adenocarcinomas, 5 cases of chronic pancreatitis, and 6 normal
pancreas samples as previously described [24]. For each cancer
case, two tumor cores and one adjacent normal core were punched
for the TMA. The TMA blocks were sectioned at 5 mm thickness,
transferred by water flotation, and dried overnight at room
temperature. The slides were dewaxed, rehydrated and antigen
retrieved on-line on the BondMax
TM autostainer (Leica Micro-
systems, Inc Bannockburn, IL). All slides were subjected to heat
induced epitope retrieval using an EDTA based retrieval solution
(Leica Microsystems) for 20 minutes. Endogenous peroxidase and
biotin were blocked. The TMA sections were incubated for
30 minutes at 1:125 with YAP1 (H-125) antibody from Santa Cruz
Biotechnology, Inc (Santa Cruz, CA). The sections were visualized
using the Bond
TM Polymer Refine Detection kit (Leica Micro-
systems) using diaminobenzidine chromogen as substrate and
scored as previously described [24]. The Wilcoxon signed-rank test
was used to compare level of YAP1 expression between the tumor
and its adjacent normal samples. The Wilcoxon rank-sum test was
used to compare the YAP1 expression between tumor and
pancreatitis as well as normal pancreas samples from a separate
group of subjects. The Pearson’s correlation coefficient was used to
estimate and test the association between nuclear YAP1 expression
and histopathological parameters (tumor grade, stage, and disease
in regional lymph nodes), and sensitivity analysis was carried out
using Kendall’s tau and Spearman’s rho.
YAP1 Immunoblotting Analysis
To achieve the necessary cell density after 48 hours of growth,
BxPC-3, PANC-1, and HPDE6 cells were seeded in the following
manner in T175 cm
2 flasks in complete growth media: two million
cells for 20–30%, four million cells for 50–70%, and seven million
cells for 100%. The cells were washed with DPBS, trypsinized, and
then counted on the Cellometer Auto T4 (Nexcelcom Biosciences,
Lawrence, MA). Four million cells were used for sub-cellular
fractionation using the BioVision Nuclear/Cytosolic Fractionation
Kit (Mountain View, CA) by following the manufacturer’s
protocol. To generate whole cell lysates one million cells were
lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA)
with 1X protease and phosphatase inhibitor cocktail (Roche) and
incubated in ice for 30 minutes. The extracts were centrifuged at
14,0006 g for 10 minutes at 4uC. Protein concentration was
determined using the bicinchoninic acid (BCA) protein assay
(Pierce Biotechnology, Rockford, IL). A total of 20 mg of protein
per lane was separated by 4–12% NuPAGE Bis-Tris gel
electrophoresis (Invitrogen). The blots were incubated with either
a Phospho-YAP1 (Ser127) antibody (Cell Signaling) at 1:2000
dilution or a total YAP1 (H-125) antibody (Santa Cruz
Biotechnologies, Santa Cruz, CA) at 1:2000 dilution overnight at
4uC and then exposed to anti-rabbit IgG HRP-linked antibody
(Cell Signaling) at 1:3000 dilution at room temperature for 1 hour.
PARP (Cell Signaling) at 1:2000 dilution served as the loading
control for the nuclear fraction, while a-tubulin (Cell Signaling) at
1:2000 dilution served as a control for the whole cell lysates and
cytosolic fraction.
siRNA treatment and Cell Proliferation Assays
YAP1 expression silencing was achieved with two YAP1 siRNA
duplex oligonucleotides targeting two different regions of YAP1
transcript (Qiagen, Valencia, CA) at a final concentration of
20 nM using the siLentfect transfection reagent (Bio-Rad)
according to the manufacturer’s protocol. The siRNAs were
reverse-transfected by incubating the siRNAs in 10 ml serum-free
RPMI 1640 cell culture media (Invitrogen) containing 50 ml of the
siLentfect lipid reagent (Bio-Rad) mix per well and arrayed into
96-well plates. The siRNAs and transfection reagent were allowed
to incubate at room temperature for 30 minutes. Afterwards, the
cells were plated to the siRNA-transfection reagent mix at 4800
cells/well and serum-supplemented at a final concentration of 5%
for BxPC-3 and 2% for PANC-1. For the HPDE6 cell line, 6000
cells/well were plated to siRNA-transfection reagent mix in the
keratinocyte medium. The plates were stored in a humidified
incubator at 37uC and 5% CO2. After 24 hours, the transfection
media was removed from each well and replaced with fresh serum-
supplemented growth media. Cell viability was determined by
adding 100 ml of the CellTiter-Glo Luminescent Assay (Promega,
Madison, WI) to each well. The plates were incubated at 37uC for
one hour, and the luminescence was recorded with the Synergy
HT microplate reader (BioTek, Winooski, VT).
Apoptosis and cell cycle analysis
The transfection of YAP1 siRNAs into the pancreatic cells lines
was as described in the cell proliferation studies above. Ninety-six
YAP1 in Pancreatic Cancer
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e32783hours after initial transfection, caspase-3 and 27 activities were
determined by adding 100 ml of the Caspase-Glo 3/7 Assay
(Promega) to each well. The plates were incubated at 37uC for one
hour, and the luminescence was recorded with the Synergy HT
microplate reader (BioTek). The caspase activity in cells treated
with siRNA was normalized to that of the Cells Only control.
Cell cycle analysis of YAP1 siRNA treated pancreatic cell lines
were as previously described [23].
Anchorage-independent assays
In 6-well plates, 250,000 cells (BxPC-3 and PANC-1) were
reverse transfected with 20 nM of the YAP1 siRNAs (Qiagen) for
48 hours (and 72 hours for protein extraction and immunoblot
analysis). Cells were washed with DPBS, trypsinized, and counted
by trypan blue exclusion. Six thousand viable BxPC-3 cells and
3,000 viable PANC-1 cells were mixed with 1 ml of growth media
and 0.3% agar and then layered onto 0.5% agar beds in 35 mm
grid dishes. Cells were allowed to grow for 21 days and the entire
area of the dish was counted. Colonies larger than 50 cells were
counted as positive for transformation. Assays were conducted in
triplicate.
Cells remaining from the transfection were kept for RNA and
protein extraction. For RNA extraction, the RNeasy Mini Kit
(Qiagen) was utilized following the manufacturer’s recommended
protocol. One microgram of total RNA was used in a 20 ml cDNA
synthesis reaction (Quantas Biosciences, Gaithersburg, MD).
Reactions were carried out in 1 ml of the cDNA reaction mix,
10 ml SYBR Green/Taq Polymerase master mix (Roche,
Indianapolis, IN), 4 ml of primers (YAP1, 59-GCCATTAAAGG-
CAGCTGTTC-39 and 59-AGCACTGTGCCAGGTATCAC-39;
GAPDH, 59-ATTGCCCTCAACGACCACTT-39 and 59-GGT-
CCACCACCCTGTTGC-39, at a final concentration 400 nM),
and 5 ml water to a final volume of 20 ml. The Bio-Rad MyIQ
single color real-time PCR detection system (Hercules, CA) was
used to perform the RT-PCR. Two-step amplification (95uC for
30 sec and 58uC for 30 sec) was repeated for 40 cycles. Following
the PCR reaction, a melting curve analysis was performed (60uC
for 5 sec) for 35 cycles. The data was analyzed using the
comparative CT method [25]. Analysis of whole cell lysate protein
level expression of YAP1 was as previously described, with the
exception that the siRNA-treatment was for 72 hrs.
Results
YAP1 is overexpressed in pancreatic ductal
adenocarcinomas (PDA)
To evaluate the expression level of YAP1 protein in PDA
tissues, we performed immunostaining using a tissue microarray
(TMA). Among the 66 PDA cases contained in the TMA, 64 were
evaluable for tumor staining, of which 33 had matching normal
epithelium. The YAP1 antibody showed both nuclear and
cytoplasmic staining, which is consistent with the known cellular
function of YAP1 protein – YAP1 is localized in cytoplasm when it
is inactivated and it is translocated into nucleus when activated.
We assessed the staining intensity for both nuclear and cytoplasmic
YAP1 and summarized the scores in Table 1. Approximately 77%
(49/64) of the PDA cases had positive (scored 1+ or higher)
nuclear YAP1 staining in tumor cells, 63% (31/49) of which had
moderate (2+) or strong (3+) staining. In contrast, only 48% (16/
33) of the cases had positive staining in the adjacent normal
epithelium, with only 18% (6/33) had moderate or strong staining.
On the other hand, the staining intensities in the cytoplasm are
comparable between the tumor and adjacent normal tissues,
where 56% (36/64) of the cases had 2+ or higher staining in the
tumor and 43% (14/33) had 2+ or higher staining in adjacent
normal epithelium. Analysis of the tumor cases with matching
adjacent normal tissues using Wilcoxon signed-rank test also
showed significantly higher expression in the tumor cells compared
to adjacent normal ductal cells with a p-value of 0.0002. But more
importantly, the difference in YAP1 protein level between tumor
and adjacent normal epithelium is much more significant in the
nucleus (p-value=0.0007) than in the cytoplasm (p-value=0.027),
indicating that YAP1 is not only overexpressed in PDA but it is
also highly activated.
Figure 1 depicts examples of differential YAP1 staining in PDA,
adjacent normal tissues, and normal pancreas. In some normal
pancreas and pancreatitis tissues we observed moderate to strong
YAP1 staining in the acinar cells and small ducts (Figure 1C).
Table 1. Summary of YAP1 immunostaining in pancreatic tumors and adjacent normal samples.
YAP1 Nuclear Expression
Staining Intensity Tumor Percent Adjacent Normal Percent
Negative=0 15 23.4% 17 51.5%
Weak=1 18 28.1% 10 30.3%
Moderate=2 19 29.7% 4 12.1%
Strong=3 12 18.8% 2 6.1%
n= 64 33
YAP1 Cytoplasm Expression
Staining Intensity Tumor Percent Adjacent Normal Percent
Negative=0 4 6.3% 2 6.1%
Weak=1 24 37.5% 17 51.5%
Moderate=2 26 40.6% 12 36.4%
Strong=3 10 15.6% 2 6.1%
n= 64 33
doi:10.1371/journal.pone.0032783.t001
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significantly higher than in the normal pancreas and pancreatitis
cases (p-value=0.011).
Next, we correlated the activated nuclear YAP1 expression level
with histopathological parameters in patients with pancreatic
cancer. As shown in Table 2, there is no association between
nuclear YAP1 expression and tumor grade or residual disease in
regional lymph nodes, but there exists a marginally significant
correlation (r=0.33 and p-value=0.068 in the Pearson correla-
tion coefficient analysis) between nuclear YAP1 level and tumor
stage.
We also examine the expression level of YAP1 in a panel of
eight human pancreatic cancer and two immortalized normal
human pancreatic epithelial cell lines using Western blotting
(Figure 2A). Six pancreatic cancer cell lines (BxPC-3, CFPAC-1,
HPAF-II, Hs 766T, MIA PaCa-2, and PANC-1) exhibited high to
moderate protein levels of YAP1. Two pancreatic cancer cell lines
(AsPC-1 and Capan-1) had undetectable to low YAP1 protein
levels, respectively. The two immortalized pancreatic cell lines
(HPDE6 and hTERT-HPNE) had low to moderate YAP1 protein
expression. This expression profile of YAP1 in pancreatic cell lines
is consistent with what we observed in the pancreatic tumor tissue
samples (Table 1).
Further investigation of YAP1 expression in xenograft tumors
formed by the pancreatic cancer cell lines also showed similar
results. Figure 2 depicts the differential staining and localization of
Figure 1. Immunohistochemical staining of YAP1 in pancreatic tumor samples. A) Negative to weak cytoplasmic staining in normal ductal
epithelium (white arrows). B) Moderate staining (mostly cytoplasmic) in normal ducts adjacent to tumor (white arrows). C) Moderate to strong
staining in a normal centroacinar and small ductal cells (white arrows); D) Weak staining in a ductal adenocarcinoma (black arrows); E) Strong staining
in a well differentiated ductal adenocarcinom (black arrows); and F) strong staining (mostly nuclear) in a poorly differentiated ductal adenocarcinoma
(black arrows).
doi:10.1371/journal.pone.0032783.g001
Table 2. Nuclear YAP1 expression level and its correlation with histopathological parameters in pancreatic cancer.
# Patients
Parameters Nuclear YAP1 expression
Pearson Correlation
Coefficient p-value Kendall’s Tau p-value Spearman’s Rho p-value
01 + 2+ 3+
Grade 1 2 2 1 0 20.157 0.398 20.121 0.451 20.142 0.445
2 4 754
3 4 110
Stage I 1 0 0 0 0.332 0.068 0.291 0.079 0.317 0.082
I I 3 310
III 6 7 6 4
I V 0 000
pN 0 4 6 2 2 0.016 0.93 0.014 0.934 0.015 0.936
1 6 452
Abbreviation: pN, pathological nodal status; 0=negative, 1=metastasis present.
doi:10.1371/journal.pone.0032783.t002
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immunohistochemistry. The AsPC-1 tumor had very low staining
of YAP1 and was limited to the cytoplasm (Figure 2B), which is in
accordance to the Western blotting results (Figure 2A). BxPC-3
and MIA PaCa-2, which had moderate to high protein expression
of YAP1 by Western blotting (Figure 2A), showed moderate to
strong immunostaining in the cytoplasm and moderate (sometimes
strong) staining in the nuclei (2C and 2D, respectively). PANC-1
had similar YAP1 protein expression with intense staining of the
cytoplasm with low to moderate staining of the nuclei (Figure 2E).
The expression and localization of YAP1 is regulated by
cell density
It has been reported that increased cell density can result in the
activation of Hippo pathway and subsequently the sequestering of
YAP1 in the cytoplasm [6]. We hypothesized that in pancreatic
cancer cells such regulation of YAP1 localization by cell density is
diminished. To explore this hypothesis, we assessed the expression
level and localization of YAP1 at varying cell densities by
subcellular protein fractionation and immunoblotting.
As shown in Figure 3, at lower cell densities (20–70%), the
YAP1 protein was present in both the cytoplasm and nucleus in
the two pancreatic cancer cell lines, BxPC-3, and PANC-1,
whereas in the immortalized normal pancreatic ductal epithelial
cell line, HPDE6, YAP1 was not detectable in the cytosolic
fraction. When cells became 100% confluent, the relative nuclear
YAP1 protein level (ratio of nuclear YAP1 vs. total YAP1)
increased in BxPC-3 and PANC-1, but not in HPDE6 (Figure S1).
Although the cytosolic YAP1 protein level increases as the cells
become confluent in all three cell lines, the increase in HPDE6 is
the most significant. This indicates that relatively more YAP1
remain activated (unphosphorylated) in the cancer cell lines than
in the immortalized normal HPDE6 cell line when cells become
confluent. The level of phospho-YAP1 (p-YAP1) protein, which is
only detected in the whole cell lysate and the cytosolic fraction in
the cell lines, also confirms the differences in YAP1 cellular
localization between the cancer cell lines and HPDE6. p-YAP1
was not detected in the cytosolic fraction of low confluent HPDE6
cells and there was a dramatic increase when the cells became
100% confluent. In the cancer cells, on the other hand, p-YAP1 is
present at low cell densities and increases as the cells become more
confluent. These results indicate that YAP1 expression and
localization is not as tightly regulated by cell density in cancer
cells as in the normal cells, suggesting that YAP1 function might be
dysregulated in pancreatic cancer cells.
siRNA knockdown of YAP1 reduces cell proliferation,
induces apoptosis, and abates anchorage-independent
growth in pancreatic cancer cell lines
To further analyze the role of YAP1 in tumorigenesis, we
examined the effect of YAP1 silencing by siRNA oligonucleotides on
pancreatic cell proliferation, apoptosis, and anchorage-independent
Figure 2. YAP1 expression in pancreatic cell lines and
xenograft tumors. A) Western blotting analysis of YAP1 protein
expression in a panel of eight pancreatic cancer and two immortalized
(non-transformed) pancreatic cell lines. B–E) Immunohistochemical
staining for YAP1 in pancreatic cancer xenografts: B) AsPC-1; C) BxPC-
3; D) MIA PaCa-2; and E) PANC-1.
doi:10.1371/journal.pone.0032783.g002
Figure 3. YAP1 protein expression and localization in pancreatic cancer cell lines. As cell density increases, the pancreatic cancer cell lines,
BxPC-3 and PANC-1, response to the deactivation of YAP1 as a transcription cofactor by cytosolic sequestration is less substantial than HPDE6. Cells
were extracted at increasing cell densities after 48 hours of initial seeding. PARP serves as the loading control for the nuclear fraction. a-tubulin serves
as the loading control for the whole cell lysates and cytosolic fraction.
doi:10.1371/journal.pone.0032783.g003
YAP1 in Pancreatic Cancer
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32783growth. BxPC-3 and PANC-1 cells were reverse-transfected with
two siRNA oligonucleotides targeting different regions of the YAP1
mRNA sequence. The AllStars Negative Control siRNA (Neg
siRNA) and AllStars Death Control siRNA (Qiagen) were used as
controls to compare siRNA transfection effects on cell proliferation
and transfection efficiency.
Over a time course of 96 hours, cells treated with YAP1 siRNA
had significant reduction in growth rates compared to the Cells
Only and negative siRNA (Neg siRNA) control. In Figure 4, the
Neg siRNA had a minimal effect on the proliferation of BxPC-3
and PANC-1 compared to the untreated Cells Only control.
However, both YAP1 siRNA sequences had significantly sup-
pressed proliferation in both BxPC-3 and PANC-1. Ninety-six
hours after siRNA treatment, siRNA sequence YAP1_1 inhibited
the growth of BxPC-3 and PANC-1 cells by 69% and 53%,
respectively (p,0.01) and the siRNA sequence YAP1_2 inhibited
the growth by 34% and 33%, respectively (p,0.05). YAP1 siRNA
sequences did not significantly reduce proliferation in HPDE6
(Figure S2A).
To evaluate the effect of YAP1 inhibition on apoptosis, we
measured the activation of caspase-3 and caspase-7 in pancreatic
cancer cells treated with siRNA. As shown in Figure 4C, 72 hours
after transfection, both YAP1 siRNA sequences induced caspase
3/7 activity by more than 2-fold (p,0.05) when compared to the
negative siRNA control in BxPC-3, while one sequence (YAP1_1)
significantly induced caspase activity (p,0.05) in PANC-1.
However, neither YAP1 siRNA sequence significantly induced
caspase 3/7 activity in the HPDE6 cells (Figure S2B). This finding
suggests that knockdown of YAP1 expression induces caspase-
dependent apoptosis in the pancreatic cancer cells.
Next, the effects of YAP1 inhibition on cell cycle distribution
were examined (Table S1). Both YAP1 siRNA sequences caused a
considerable increase in the G0/G1 cell population in both BxPC-
3 and PANC-1, comparing to the negative siRNA control. In
HPDE6, the two siRNA sequences did not induce consistent
effects on cell cycle distribution when compared to the Neg siRNA
control (Table S1).
Since we observed a significant effect on cell proliferation, we
wanted to consider if YAP1 knockdown by siRNA would abolish
anchorage-independent growth of pancreatic cancer cells. BxPC-3
and PANC-1 cells were treated with the siRNA sequences for
48 hrs and harvested by trypsinization. Equal number of viable
cells for each treatment was then seeded on soft agar. After 21
days, colonies were counted from each group and then normalized
to the Cells Only control and represented as a percentage of
colonies. Both YAP1_1 and YAP1_2 siRNAs suppressed clono-
genicity in soft agar in BxPC-3 (95%, p,0.01) and in PANC-1
(60%, p,0.05) (Figure 5A). In contrast to the similar inhibitory
activity in the cell proliferation assay (Figure 4A and 4B), the
reduction in colony formation was much greater in BxPC-3 cells
(,95%) than that in PANC-1 cells (,60%). This difference is
consistent with the level of YAP1 mRNA and protein reduction by
the siRNA oligonucleotides in the cell lines (Figure 5B and 5C). As
shown in Figure 5C, the reduced protein expression by YAP1
siRNAs is more dramatic in BxPC-3 cells than in PANC-1 cells.
Discussion
Originally discovered in Drosophila as a potent pathway for
tumor suppression, the Hippo pathway negatively regulates cell
growth through a kinase cascade and results in the inactivation of
Yki (YAP1 in mammals) [6,7,9,10]. The pathway and its
components are highly conserved in mammals, and multiple
studies have demonstrated the pathway’s compelling roles of
regulation of cell growth, proliferation, survival, and association in
malignancies [26–33]. As the nuclear effector of transcription,
YAP1 has become an attractive target of investigation in
mammalian malignancies. In our study, we have observed that
YAP1 is overexpressed in pancreatic tumors and in cancer cell
lines. The down-regulation of YAP1 diminished cell viability,
proliferation, and anchorage-independent growth in cultured cells.
The subcellular localization of YAP1 in the pancreatic tumors
and in the cultured cell lines highlighted the dysregulation of the
Hippo pathway. Upon pathway activation, YAP1 is inactivated via
phosphorylation by LATS1/2 and consequently retained in the
cytoplasm [6,7]. In our immunostaining studies, YAP1 staining is
generally more intense in the cytoplasm than in the nucleus, and
the tumor has a significantly higher proportion of cells with
Figure 4. Effect of YAP1 targeted siRNAs on the proliferation
and apoptosis of pancreatic cancer cell lines. The cell growth
curves of A) BxPC-3 and B) PANC-1 transfected with YAP1 siRNA
oligonucleotides. The independent two-sample t test (two-tailed) was
utilized to calculate the statistical significance at the 96-hour time point
compared to Neg siRNA. * denotes p,0.05, and ** denotes p,0.01. C)
The Caspase-Glo 3/7 Assay (Promega) was used to determine the level
of apoptosis in pancreatic cancer cells transfected with YAP1 siRNA
oligonucleotides after 72 hours. ** denotes an independent two-
sample t test (two-tailed) p-value of ,0.01 when compared to the
negative siRNA control (Neg siRNA).
doi:10.1371/journal.pone.0032783.g004
YAP1 in Pancreatic Cancer
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(77% vs. 48%). Although a significant percentage of adjacent
normal cases stained positive for YAP1, the overall expression level
is significantly higher in the tumor (Table 1). The staining of YAP1
in normal pancreas tissues is restricted to acinar cells and small
ducts, which is consistent with a previous study [34] and likely
represents the normal function of YAP1 in maintaining tissue
homeostasis.
As a previous study [6] and ours have observed, YAP1 protein
expression is modulated by increasing density. At low density,
YAP1 protein expression is minimal, but as cell density increases
YAP1 expression increases accordingly. In Figure 3, a slower
migrating band was observed in the pancreatic cancer cell lines
immunoblotted for total YAP1 when cell density reached 100% in
the whole cell lysate and nuclear fractions. We postulate that the
slower migrating band observed in the nuclear fraction is not due
to the phosphorylation known to regulate YAP1 localization, but
rather a post-translational modification unknown at this time [35–
38]. For future studies, the cell density should be noted in
relationship to YAP1 protein expression. In pancreatic cell lines,
YAP1 protein expression and localization is regulated by cell
density, but such regulation seemed to be diminished significantly
in cancer cells compared to that in normal ductal epithelial cells
(Figure 3). Interestingly, although we see high levels of YAP1
Figure 5. Inhibition of anchorage-independent growth of pancreatic cancer cells by YAP1 siRNA oligonucleotides. A) Percentage of
colonies relative to the Cells Only control on soft agar after 21 days of growth from initial seeding. p-values were calculated by comparing the YAP1
siRNA (YAP1_1 and YAP1_2) to the Neg siRNA (independent two tailed t test, two-tailed). B) qPCR analysis of YAP1 mRNA expression after 48 hours of
siRNA transfection. C) Western blotting analysis of YAP1 expression after siRNA-treatment for 72 hrs. The samples for each cell line were separated
and analyzed on the same blot.* denotes p,0.05, and ** denotes p,0.01.
doi:10.1371/journal.pone.0032783.g005
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YAP1 protein level had more significant increase than the
cytoplasmic YAP1 when compared to adjacent normal tissues
(Table 1). This perhaps indicates that, in addition to the
upregulation of YAP1 protein expression, components of the
Hippo pathway that regulate YAP1 localization (phosphorylation)
might also be dysregulated in pancreatic cancer. In fact, the
LATS1/2 kinases upstream of YAP1 have been shown to be
down-regulated in several cancer types including soft tissue
sarcoma [39], astrocytoma [40], and breast cancer [41,42]. Most
recently, Zhou et al. reported the loss of active MST1, another
kinase upstream of YAP1, in human hepatocellular carcinomas
(HCC) and are tumor suppressive in transgenic mouse models
[43–45]. Investigation of these upstream regulators of YAP1 in
pancreatic cancer will shed further light on the role of Hippo
pathway in the tumorigenesis and progression of pancreatic
cancer.
Although the oncogenic activity of YAP1 has been clearly
demonstrated [11,12], data from some studies also indicate that
YAP1 might be tumor suppressive in certain cell types. For
example, it has been shown that activated nuclear YAP1 forms a
complex with the p73 tumor suppressor protein and prevents the
latter from being degraded, which, in turn, results in increased
apoptosis. In our work, we demonstrate that suppression of YAP1
expression by siRNA reduced pancreatic cell growth and
clonogenicity, which is consistent with the notion that YAP1 is
an oncogene. Our findings are also in agreement with the results
obtained from HCC models using YAP1 targeted shRNA, siRNA,
and miRNA constructs [12,28,46]. It is possible that in different
tissues and/or under different conditions, YAP1 interacts with
different partners to exert different functions [27,28]. In
conclusion, our study shows that YAP1 is overexpressed in
pancreatic cancer and offers a mechanistic insight into the
phenotypic effect of the down-regulation of YAP1. YAP1 and its
downstream effectors represent potential new therapeutic targets
in pancreatic cancer.
Supporting Information
Figure S1 Quantification of YAP1 protein expression at
different cell densities. The total YAP1 protein in the nuclear
fraction and the whole cell lysate in BxPC-3, PANC-1, and
HPDE6 cells with increasing cell densities shown in Figure 3 were
quantified by densitometry and normalized to the loading controls
(nuclear=PARP; whole cell lysate=alpha-tubulin). The ratios of
the normalized values of total YAP protein in the nuclear fraction
to the whole cell lysate were calculated and graphed.
(TIF)
Figure S2 Effect of YAP1 targeted siRNAs on the
proliferation and caspase activation in HPDE6 cells. A)
The relative proliferation rates of HPDE6 cells after 72 and
96 hours of YAP1 siRNA treatment. B) Caspase 3/7 activity levels
in HPDE6 cells treated with YAP1 siRNA oligonucleotides for
72 hours.
(TIF)
Table S1 Effects of YAP1 siRNA treatment on cell cycle
in pancreatic cell lines. The cell cycle distribution was
measured using FACS analysis 72 hours after the transfection of
siRNA oligonucleotides in BxPC-3, PANC-1, and HPDE6 cell
lines.
(DOCX)
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